Helixgate

Helixgate

Uncategorized

Scramblase Dynamics Uncovered by Single-Vesicle Fluorescence Microscopy

Published

on

A new single-protein analysis technique gives researchers newfound ability to study scramblases, physiologically important proteins that translocate phospholipids bidirectionally across cell membranes.  

In the study published in Nature Structural & Molecular Biology titled, A single-vesicle fluorescence microscopy platform to quantify phospholipid scrambling, researchers from Weill Cornell Medicine and Ruhr University Bochum have developed a fluorescence imaging-based technique to measure the activity rates of individual scramblase proteins. 

“I’m excited about this new platform as it is versatile and provides unprecedented information on exactly how fast a single scramblase works,” said Anant Menon, PhD, professor of biochemistry and biophysics at Weill Cornell Medicine and co-corresponding author of the study.

Scramblases are key drug targets with roles in the assembly of cell membranes, modification of proteins with sugars, cell survival, muscle development and molecular trafficking. Yet, strategies for understanding scramblase dynamics have been limited.

Traditionally, researchers purify scramblase proteins for further study using vesicles to record average scramblase activity. However, this bulk approach is unable to measure the transport rate of individual scramblases and capture how scramblase variability impact biological processes.

The authors used fluorescently-tagged scramblases to achieve high resolution and evaluated a scramblase protein, known as VDAC1, best known as a membrane channel protein within mitochondria. Two copies of VDAC must align to provide a pathway for lipid movement. These dimers have a wide range of scrambling rates, from fewer than 100 to more than 1,000 lipids per second.

“These findings indicate that only certain dimer conformations are capable of rapid scrambling, directly validating predictions from computer simulations,” Menon said.

The team demonstrated the versatility of their approach by applying the platform to measure lipid-scrambling by opsin, a cell-membrane receptor and scramblase that is involved in light-detection in the eye. Results showed that individual opsin proteins scramble lipids faster than VDAC dimers, achieving rates in excess of 10,000 lipids per second.

The new platform can study how drug molecules impact scramblase function. Additionally, the authors aim to combine their functional studies of scramblases with high-resolution imaging to understand how scramblase shape relates to activity rates. The team also plans to use the technique to study other lipid-moving proteins called flippases and floppases.

The post Scramblase Dynamics Uncovered by Single-Vesicle Fluorescence Microscopy appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

FTC, four state AGs sue transgender health group over care standards

The Federal Trade Commission and four state attorneys general have sued the main professional organization for gender-affirming care clinicians, alleging it made false claims to sell medical services to kids.

The lawsuit against the World Professional Association for Transgender Health, filed Wednesday in a federal court in Texas, is part of the Trump administration’s broader effort to end gender-affirming care for minors. 

Read the rest…

Read More

Published

on

The Federal Trade Commission and four state attorneys general have sued the main professional organization for gender-affirming care clinicians, alleging it made false claims to sell medical services to kids.

The lawsuit against the World Professional Association for Transgender Health, filed Wednesday in a federal court in Texas, is part of the Trump administration’s broader effort to end gender-affirming care for minors. 

Read the rest…

Read More

Continue Reading

Uncategorized

Luigi Mangione will assert psychiatric defense in murder case in UnitedHealthcare CEO’s killing

NEW YORK — Luigi Mangione plans to assert a psychiatric defense at his state murder trial, claiming he was suffering from extreme emotional disturbance when he gunned down UnitedHealthcare CEO Brian Thompson, a judge said Wednesday. That could mean less prison time if he’s convicted.

A jury that accepts such a defense would be obligated to convict Mangione of manslaughter, which carries a maximum sentence of 25 years in prison, instead of murder, which could put him behind bars for the rest of his life. An emotional disturbance defense isn’t available in Mangione’s federal case, where he also faces a possible life sentence.

Read the rest…

Read More

Published

on

NEW YORK — Luigi Mangione plans to assert a psychiatric defense at his state murder trial, claiming he was suffering from extreme emotional disturbance when he gunned down UnitedHealthcare CEO Brian Thompson, a judge said Wednesday. That could mean less prison time if he’s convicted.

A jury that accepts such a defense would be obligated to convict Mangione of manslaughter, which carries a maximum sentence of 25 years in prison, instead of murder, which could put him behind bars for the rest of his life. An emotional disturbance defense isn’t available in Mangione’s federal case, where he also faces a possible life sentence.

Read the rest…

Read More

Continue Reading

Uncategorized

UniQure to file gene therapy for approval, reflecting major shifts at FDA

The decision marks another regulatory U-turn following the exits of Marty Makary and Vinay Prasad, suggesting to some analysts that current FDA leadership may be more flexible in certain cases. 

Read More

Published

on

The decision marks another regulatory U-turn following the exits of Marty Makary and Vinay Prasad, suggesting to some analysts that current FDA leadership may be more flexible in certain cases. 

Read More

Continue Reading
Advertisement

Trending